Rocket Pharmaceuticals Inc (RCKT) Receives Average Recommendation of “Hold” from Brokerages

Shares of Rocket Pharmaceuticals Inc (NASDAQ:RCKT) have been given an average broker rating score of 3.00 (Hold) from the one brokers that provide coverage for the stock, Zacks Investment Research reports. One analyst has rated the stock with a hold rating.

Zacks has also given Rocket Pharmaceuticals an industry rank of 196 out of 265 based on the ratings given to its competitors.

RCKT has been the subject of several recent analyst reports. ValuEngine raised Rocket Pharmaceuticals from a “strong sell” rating to a “sell” rating in a report on Tuesday, January 9th. BidaskClub raised Rocket Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a report on Friday, January 5th.

Shares of Rocket Pharmaceuticals (NASDAQ RCKT) traded up $1.60 during midday trading on Friday, hitting $16.64. The stock had a trading volume of 580,544 shares, compared to its average volume of 370,062. Rocket Pharmaceuticals has a 52 week low of $3.40 and a 52 week high of $17.45. The company has a quick ratio of 27.63, a current ratio of 27.63 and a debt-to-equity ratio of 0.97. The stock has a market capitalization of $102.36, a price-to-earnings ratio of -2.72 and a beta of 3.16.

TRADEMARK VIOLATION NOTICE: This piece of content was first posted by American Banking News and is the sole property of of American Banking News. If you are reading this piece of content on another domain, it was illegally stolen and reposted in violation of international copyright and trademark laws. The original version of this piece of content can be read at https://www.americanbankingnews.com/2018/01/27/rocket-pharmaceuticals-inc-rckt-receives-average-recommendation-of-hold-from-brokerages.html.

About Rocket Pharmaceuticals

Rocket Pharmaceuticals, Inc, formerly Inotek Pharmaceuticals Corporation, is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of therapies for glaucoma and other diseases of the eye. Its lead product candidate, trabodenoson, is a selective adenosine mimetic that the Company has designed to lower intraocular pressure (IOP) by restoring the eye’s natural pressure control mechanism.

Get a free copy of the Zacks research report on Rocket Pharmaceuticals (RCKT)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Rocket Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Rocket Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply